Risk Stratification in HPV-Associated Oropharyngeal Cancer: Limitations of Current Approaches and the Search for Better Solutions
Cancers · 22.01.2025 · 17 (3) · 357
DOI: 10.3390/cancers17030357 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.01.2025. Verfasst von Bailey Fabiny Garb und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
The rising incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) necessitates advancements in risk stratification to optimize treatment outcomes and improve the quality of life for patients. Despite its favorable prognosis compared to HPV-negative OPSCC, current clinical staging and biomarkers, such as p16 status, are limited in their ability to distinguish between high- and low-risk patients within HPV-associated OPSCC. This limitation results in the overtreatment of low-risk patients, exposing them to unnecessary toxicity, and the undertreatment of high-risk patients who require more aggressive interventions. This review critically evaluates current stratification methods, including clinical assessments, de-escalation trials, and candidate molecular biomarkers for risk stratification. Emerging approaches such as immune markers, viral genomic integration patterns, and other molecular markers offer promising avenues for enhanced prognostic accuracy. By integrating advanced risk stratification methods, tailored treatment approaches may one day be developed to balance oncologic efficacy with reduced treatment-related morbidity. This review underscores the need for continued research into predictive biomarkers and adaptive treatment strategies to better address the diverse risk profiles of HPV-associated OPSCC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
- Department of Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC 20007, USA.
- Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI 48019, USA.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
- Biostatistics Department, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Elham Mohebbi, Shaomiao Xia, Nisha J D'Silva, Maureen A Sartor
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIEHS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Garb, B. F., Mohebbi, E., Lawas, M., Xia, S., Maag, G., Ahn, P. H., D'Silva, N. J., Rozek, L. S., & Sartor, M. A. (2025). Risk Stratification in HPV-Associated Oropharyngeal Cancer: Limitations of Current Approaches and the Search for Better Solutions. Cancers, 17(3), 357. https://doi.org/10.3390/cancers17030357
Vancouver
Garb BF, Mohebbi E, Lawas M, Xia S, Maag G, Ahn PH, et al. Risk Stratification in HPV-Associated Oropharyngeal Cancer: Limitations of Current Approaches and the Search for Better Solutions. Cancers. 2025;17(3):357. doi:10.3390/cancers17030357
BibTeX
@article{Garb2025,
author = {Garb, Bailey Fabiny and Mohebbi, Elham and Lawas, Maria and Xia, Shaomiao and Maag, Garett and Ahn, Peter H and D'Silva, Nisha J and Rozek, Laura S and Sartor, Maureen A},
title = {Risk Stratification in HPV-Associated Oropharyngeal Cancer: Limitations of Current Approaches and the Search for Better Solutions},
journal = {Cancers},
year = {2025},
volume = {17},
number = {3},
pages = {357},
doi = {10.3390/cancers17030357}
}
EUVIMED